Last month, a 34-year-old patient came to my clinic with a stack of examination reports from other hospitals. Her first question was: "I found over a dozen hospitals online claiming to offer third-generation IVF. Some say they have the qualification, others say they collaborate with a certain center. How can I tell which one is truly compliant?" This question appears almost weekly in the consultation room. By the end of 2024, more than 100 medical institutions nationwide have been approved by the National Health Commission to perform Preimplantation Genetic Testing (PGT). However, the information online is mixed, leaving patients more confused than ever when making a choice.
What is Third-Generation IVF Qualification and Why Do Only Over 100 Hospitals Have It?
Third-generation IVF is medically termed Preimplantation Genetic Testing (PGT). It involves testing embryos cultured in vitro at the gene or chromosome level, based on conventional IVF, to select embryos with normal genetic material for transfer. This technology involves complex procedures such as embryo biopsy, single-cell amplification, and high-throughput sequencing, demanding extremely high standards for laboratory conditions, personnel qualifications, and quality control systems.
The National Health Commission has very strict approval procedures for PGT technology. For a fertility center to obtain third-generation IVF qualification, it typically needs to meet the following conditions:
- Has obtained qualification for conventional In Vitro Fertilization-Embryo Transfer (IVF-ET) and operated stably for at least 3 years
- Has an independent embryo biopsy laboratory and genetic testing platform
- Employs professionally trained embryologists and genetic counseling teams
- Has completed a specified number of PGT clinical validation cases and passed expert review
This is why, although there are hundreds of assisted reproductive institutions nationwide, only over a hundred have third-generation IVF qualification—the technical threshold and regulatory requirements mean this is not a service that can be quickly launched.
How to Confirm if a Hospital Has Third-Generation IVF Qualification
Confirming the qualification is the first and most crucial step in choosing a hospital. The following four methods can help patients make an accurate judgment:
| Verification Method | Specific Approach | Points to Note |
|---|---|---|
| Official Website of Health Commission | Log in to the official website of the National Health Commission or provincial health commission, and search in the "List of Assisted Reproductive Technology Institutions" | Check if the approved items include "Preimplantation Embryo Genetic Diagnosis Technology" |
| Check Hospital Qualification Certificate | Request the hospital to present the "Certificate of Approval for Human Assisted Reproductive Technology" | The certificate will clearly specify the permitted technology types, including PGT-A, PGT-M, PGT-SR |
| Distinguish "Trial Operation" from "Formal Operation" | Trial operation qualification is valid for 1 year and requires re-evaluation upon expiry; formal operation is a long-term qualification | Trial operation qualification is also legal, but indicates the center has been performing PGT for a shorter period |
| Beware of "Collaborative Laboratory" Model | Some institutions claim to collaborate with qualified third-party laboratories for PGT | Compliant third-generation IVF requires embryo biopsy and testing to be completed within the same hospital. Sending specimens out carries legal and technical risks. |
In clinical practice, we find some patients are attracted by claims like "The director of this center is a national PGT authority," but overlook that the center itself has not obtained PGT qualification. Qualification should be judged based on the institution, not the individual.
Who is Suitable for Third-Generation IVF? When Should It Be Considered?
PGT technology has clear medical indications. Not everyone needs it, and not everyone is suitable for it. According to the "Technical Specifications for Preimplantation Genetic Testing," the main indications include:
Chromosomal Structural Abnormalities
Such as balanced translocation, Robertsonian translocation, inversion, etc. PGT-SR can screen for embryos with normal chromosomal structure.
Monogenic Genetic Diseases
Such as thalassemia, spinal muscular atrophy, hereditary deafness, etc. PGT-M can block the intergenerational transmission of the disease.
Recurrent Miscarriage
Two or more spontaneous miscarriages, after excluding uterine factors, endocrine factors, etc. PGT-A can reduce the risk of miscarriage caused by embryonic aneuploidy.
Advanced Maternal Age
Female age ≥ 38 years, the rate of embryonic aneuploidy increases significantly. PGT-A can improve the implantation rate per single transfer.
Severe Male Factor
Such as severe oligoasthenospermia, non-obstructive azoospermia. The rate of chromosomal abnormalities in sperm may be increased.
Previous PGT History
If a previous transfer failed or pregnancy was terminated due to embryonic genetic abnormalities, PGT is recommended for subsequent attempts.
When is it not suitable: Severely diminished ovarian function, inability to obtain a sufficient number of eggs for biopsy; genetic issues that PGT technology cannot detect (such as some polygenic diseases); the couple has not completed necessary genetic counseling and informed consent.
Different Age Groups Have Different Priorities for Third-Generation IVF
Age is a core variable influencing third-generation IVF strategy. The medical considerations and decision-making priorities vary significantly across different age groups:
| Age Group | Main Considerations | Issues to Note |
|---|---|---|
| <35 years | Usually undergo PGT for clear genetic indications (e.g., chromosomal translocation, monogenic disease). Embryonic aneuploidy rate is relatively low. | Do not blindly undergo PGT-A just to "improve success rate." Weigh the potential impact of biopsy on the embryo. |
| 35-37 years | Embryonic aneuploidy rate begins to rise. PGT-A can help screen for euploid embryos, improving transfer efficiency. | Assess comprehensively based on the number of eggs retrieved and embryos formed, to avoid having no transferable embryos due to PGT. |
| 38-41 years | Embryonic aneuploidy rate increases significantly (approximately 40-60%). The value of PGT-A is most prominent. | May require multiple ovarian stimulation cycles to accumulate embryos, testing ovarian function and psychological resilience. |
| ≥42 years | Embryonic aneuploidy rate exceeds 70%. PGT-A can prevent transferring abnormal embryos, but the number of eggs and embryos is usually low. | Full communication is needed: there may be no embryos for transfer, or multiple cycles may be needed to obtain 1-2 euploid embryos. |
In clinical decision-making, age is not the sole determining factor. It needs to be combined with ovarian reserve indicators (AMH, antral follicle count), previous obstetric history, type of genetic disease, etc., for a comprehensive assessment. The strategy for a 42-year-old patient with normal AMH and a clear genetic indication will be completely different from that for a 38-year-old patient with AMH below 0.5.
The Most Easily Overlooked Detail: Genetic Counseling is Not a Mere Formality
In the third-generation IVF process, genetic counseling is the step most likely to be underestimated by patients. Many patients think genetic counseling is just "signing papers, going through the motions." In reality, it is the core step determining whether the PGT plan is reasonable.
Standard genetic counseling includes:
- Proband Confirmation: If PGT-M is done for a specific genetic disease, it is necessary to first confirm the accuracy of the genetic diagnosis of the proband (usually the affected child or the patient themselves).
- Family Pedigree Verification: Some genetic diseases require samples from both partners and their immediate relatives for linkage analysis to design a reliable PGT testing plan.
- Genetic Pattern Analysis: Distinguishing between autosomal dominant, recessive, X-linked, or mitochondrial inheritance. Different patterns directly impact the design of the PGT plan.
- Disclosure of Testing Limitations: PGT cannot detect all genetic problems, such as some mosaicism, de novo mutations, polygenic diseases, etc.
A patient who had failed two PGT-A transfers came to me. Reviewing her previous medical records, I found she had only undergone basic PGT-A (detecting chromosomal number and large structural abnormalities), but she actually had a clear family history of a monogenic disease and needed PGT-M. This is a case of plan mismatch due to inadequate genetic counseling.
Common Pitfalls: Be Wary of These Marketing Claims
In the clinic, I often hear patients influenced by certain marketing claims. Here are several common situations:
- "We collaborate with a laboratory in Beijing/Shanghai, the results are the same": Compliant PGT requires embryo biopsy and testing to be completed within the same medical institution. Sending specimens out poses risks of sample mix-up, transportation issues, and legal traceability problems. Qualification is granted to the institution, not the laboratory.
- "Third-generation IVF success rate is over 90%": Any discussion of success rates without considering specific age, cause, and number of embryos is not rigorous. "Success" in PGT involves multiple stages including egg retrieval rate, fertilization rate, blastocyst formation rate, testing success rate, and implantation rate. A single number has no reference value.
- "PGT-A can screen for all chromosomal problems": PGT-A mainly detects chromosomal number abnormalities and large structural abnormalities (>10Mb). Small deletions, duplications, and some mosaicism may be missed. PGT-M can only detect known specific gene mutations.
- "Third-generation IVF is more advanced than first and second generation, so it's best to go straight for third generation": The three technologies have different indications. For young patients without genetic indications, undergoing PGT not only increases cost and biopsy risk but may also reduce the final number of transferable embryos due to testing损耗.
Standard Process of Third-Generation IVF: How Long Does It Take from Initial Consultation to Transfer?
The entire third-generation IVF cycle usually takes 3-6 months, depending on the complexity of genetic counseling, the stimulation protocol, and the embryo testing period. Here is a typical process schedule:
Frequently Asked Questions
Q: How much does third-generation IVF cost?
In China, the cost of third-generation IVF is usually 30,000 to 60,000 RMB higher than conventional IVF, with total expenses typically ranging from 80,000 to 150,000 RMB. The differences mainly come from: type and dosage of stimulation drugs (domestic vs. imported), number of embryos undergoing PGT (charged per embryo), whether multiple stimulation cycles are needed to accumulate embryos, and any additional genetic counseling or family testing fees.
Q: Can I choose a hospital qualified for third-generation IVF based on rankings?
There is currently no official "ranking of third-generation IVF hospitals." Rankings circulating online are mostly based on patient reviews, self-reporting, or commercial platform data, and their reference value is limited. A more reliable approach is to start with the list of qualified institutions from the Health Commission, then select a center with experience in your specific condition based on your etiology.
Q: What materials need to be prepared in advance for third-generation IVF?
ID cards of both partners, marriage certificate, all previous medical reports (especially chromosome and genetic reports). If family verification for a genetic disease is involved, relatives need to be contacted in advance to cooperate with sampling. Some centers require infectious disease screening reports from the last 3 months.
Q: Does embryo biopsy harm the embryo?
The currently widely used blastocyst-stage biopsy (taking 3-5 trophectoderm cells) is a very mature technique. Studies show it has a minimal impact on the embryo's subsequent developmental potential. However, any procedure carries risks, including embryo developmental arrest after biopsy or testing failure, with an incidence rate of about 1-3%.
Q: Why did transfer still fail even though PGT results were normal?
Normal PGT results indicate no abnormalities were found in the embryo's chromosomes or specific genes. However, embryo implantation is also influenced by factors such as the uterine environment, immune factors, and endocrine status. Additionally, PGT has technical resolution limitations, and very rare mosaicism or minor abnormalities may be missed.
Observation from a Practitioner: Qualification is Just the Starting Point, Experience is Equally Important
As a reproductive specialist, I want to say: Qualification is a hard threshold, but experience is a soft power. A hospital having PGT qualification does not mean it has extensive testing experience in all types of genetic diseases.
For example, a center might complete a large number of PGT-A cases annually but very few PGT-M cases. For rare monogenic diseases, its plan design capability may not be as strong as a center specializing in that area. Therefore, when choosing, besides confirming the qualification, you can also inquire about:
- The center's PGT cycle volume in the last 3 years (especially cases related to your etiology)
- Whether it has an independent genetic counseling clinic
- Whether the embryology laboratory has its own platforms for single-cell amplification and high-throughput sequencing
- Whether it participates in domestic or international clinical research or quality control projects related to PGT
Risk Reminder: Third-Generation IVF is Not a "Universal Insurance"
Finally, it must be clarified: PGT technology cannot guarantee a 100% pregnancy success rate, nor can it eliminate all genetic risks. When choosing a fertility center, one should view qualifications and marketing claims rationally, focusing on medical evaluation and plan suitability. Be wary of information online claiming "guaranteed success," "guaranteed gender selection," or "third-generation IVF available without medical indications"—these not only violate the "Measures for the Administration of Human Assisted Reproductive Technology" but also carry serious medical and legal risks.
It is recommended that couples planning for third-generation IVF first complete an evaluation at a joint reproductive-genetic clinic in a regular hospital to confirm the medical necessity, and then choose a medical center with the corresponding qualification.
Comments (0)